In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a "Successor" period from 6/25/25 to 6/30/25 Combined End of Period Subscribers of 3.2 million; Combined End of Period Clinical Subscribers of 127 thousand Combined Revenues of $189 million, down 6% vs. prior year; Combined Clinical Revenues of $31 million, up 55% vs. prior year Predecessor Net Income of $1,191 million and Net Margin of 673% were impacted by Reorganization items; Successor Net ...